Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Marvel Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$3,755,053

3,774 payments

Through program year 2025, Marvel Clinical Research is reported as receiving $3,755,053 in research payments, across 3,774 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $49,383 11
2024 Research $378,011 47
2023 Research $636,097 685
2022 Research $2,038,935 3,002
2021 Research $202,078 7
2020 Research $50,446 6
2019 Research $400,102 16

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $2,458,386 3,615 payments
  2. Pfizer Inc. $462,581 66 payments
  3. Roche Molecular Systems, Inc. $239,952 37 payments
  4. E.R. Squibb & Sons, L.L.C. $165,173 4 payments
  5. Merck Sharp & Dohme Corporation $129,193 5 payments
  6. Mitsubishi Tanabe Pharma Development America, Inc. $97,523 6 payments
  7. ACADIA Pharmaceuticals Inc $92,405 10 payments
  8. Sanofi US Services Inc. $73,237 3 payments
  9. Roche Diagnostics Operations, Inc. $26,674 3 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $8,250 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $1,921,660 2,977 payments
  2. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $467,426 553 payments
  3. A Phase 3 Randomized Doubleblind Activecontrolled Multicenter Study of the Longterm Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip Or Knee $284,210 13 payments
  4. Rd006702 $165,999 27 payments
  5. A Phase 3 Randomized Withdrawal and Doseup Titration Multicenter Extension Study Investigating the Safety Efficacy and Tolerability of Ritlecitinib in Adult and Adolescent Participants With Nonsegmental Vitiligo $129,384 20 payments
  6. A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to $118,258 1 payment
  7. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 Laboratory-confirmed SARS-CoV-2 Infection With Symptoms in Adults Residing With a Person With COVID-19 $111,043 4 payments
  8. Rd006703 $100,627 13 payments
  9. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents With Erythropoietic Protoporphyria Or X-Linked Protoporphyria $87,133 4 payments
  10. Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD $73,237 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record